Clinical Trial Update: Raloxifene Use for The Heart [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating raloxifene for heart-related outcomes in cardiovascular disease and breast cancer contexts has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cardiovascular Disease

Drugs mentioned

• Evista (raloxifene)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Cardiovascular Diseases, Breast Neoplasms | Phase 3 | Status: COMPLETED